SCHEMBL24726540

SCHEMBL24726540

C=C(OCC)c1ccc2c(c1)COC(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
SMYD3 Q9H7B4 4/20 0.37
PRF1 P14222 1/20 0.35
LMNA P02545 1/20 0.35
KCNH2 Q12809 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
CYP2C19 P33261 1/20 0.34
CPT2 P23786 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26123338 0.77 PRF1 (0.56) PRF1LMNAKCNH2ALDH1A1GAA
SCHEMBL24427973 0.77 LMNA (0.54) LMNAALDH1A1GAATSHRMAPT
SCHEMBL25184590 0.76 CYP11B1 (0.47) PDE3BPDE3ACYP11B1CYP11B2SMYD3
SCHEMBL24726554 0.76 SMYD3 (0.38) SMYD3LMNAALDH1A1CYP2C9ALOX15
SCHEMBL14815941 0.74 PDE3B (0.54) PDE3BPDE3AALDH1A1GAAMAPT
SCHEMBL25845703 0.74 SIRT2 (0.48) PDE3BPDE3ACYP11B1CYP11B2SMYD3
SCHEMBL434348 0.73 CYP11B1 (0.51) PDE3BPDE3ACYP11B1CYP11B2KCNH2
SCHEMBL25190549 0.72 LMNA (0.32) PDE3BPDE3ALMNATSHR
SCHEMBL4395266 0.72 CYP11B1 (0.46) PDE3BPDE3ACYP11B1CYP11B2SMYD3
SCHEMBL2056370 0.72 PARP1 (0.51) PDE3BPDE3ACYP11B1CYP11B2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 PDE3B 2430/4885PDE3A 2189/4885CYP11B1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.